The growth rate for the domestic Indian pharmaceutical market is set to rise
over medium-term, according to Barclays Capital Equity Research report - India Healthcare & Pharmaceuticals.
- The revenue CAGR (compund annual growth rate) over the past three years had been 12.4 percent, but it is expected to be up at 15.3 percent from FY12 to FY14
- The growth is expected due to factors like new product launches, focus on improving effectiveness of field force additions and favourable pricing environment
- Most of the pharma companies are expecting to continue with product launches in India over the next 2-3 years.
- While the net revenue CAGR from Indian coverage group has been 20% over FY2005-12, the US revenue CAGR for the group has been 24.5%, accounting for a large portion of the growth.
- While previously there were no Indian companies in the top-20 generics firms in the US, currently 4-5 of Indian firms are present in this list, according to 2011 prescription trends (IMS data).
No comments:
Post a Comment